Affinity Asset Advisors LLC Makes New Investment in ProQR Therapeutics (NASDAQ:PRQR)

Affinity Asset Advisors LLC bought a new stake in ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,825,000 shares of the biopharmaceutical company's stock, valued at approximately $7,486,000. ProQR Therapeutics comprises 1.0% of Affinity Asset Advisors LLC's investment portfolio, making the stock its 28th largest position. Affinity Asset Advisors LLC owned 3.46% of ProQR Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PRQR. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at $32,000. ADAR1 Capital Management LLC acquired a new position in ProQR Therapeutics in the 4th quarter valued at about $54,000. Ballentine Partners LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at approximately $61,000. Jump Financial LLC acquired a new stake in ProQR Therapeutics during the 4th quarter worth approximately $71,000. Finally, Prudential Financial Inc. grew its stake in shares of ProQR Therapeutics by 109.1% in the 4th quarter. Prudential Financial Inc. now owns 27,600 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 14,400 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PRQR has been the topic of a number of analyst reports. Citigroup upgraded shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a research report on Monday, March 10th. Chardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th. Oppenheimer began coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They set an "outperform" rating and a $15.00 price target on the stock. Finally, HC Wainwright upped their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.

ProQR Therapeutics Stock Performance

Shares of PRQR stock remained flat at $1.14 during trading hours on Friday. 464,845 shares of the stock traded hands, compared to its average volume of 586,971. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62. The business's 50-day moving average price is $1.74 and its two-hundred day moving average price is $2.52. The stock has a market cap of $119.94 million, a price-to-earnings ratio of -3.56 and a beta of 0.25.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).